Porvac®猪瘟亚单位疫苗七年接种实现无病毒循环的群体免疫
本研究报道古巴青年岛使用猪瘟亚单位疫苗Porvac®七年的效果。抗E2抗体从接种前43.5%升至接种后6个月97.6%,保护性中和抗体滴度从基线24%升至88.4%并维持约90%,未检出病毒RNA,2018年以来无猪瘟疫情。
要点
- Porvac®接种后6个月抗E2抗体阳性率从43.5%升至97.6%。
- 保护性中和抗体滴度从基线24%升至88.4%,研究期间维持约90%。
- 200份血清在0和60个月均未检出病毒RNA,2018年后无疫情。
核心结论
- 持续群体免疫、Erns血清阳性率下降及无病毒循环表明Porvac®有助于该地区猪瘟有效控制。
研究设计与样本
- 此后仔猪2-3周龄接种,种猪每年接种两次,并进行血清学监测和病毒RNA检测。
主要发现
- 抗E2抗体阳性率从接种前43.5%升至接种后6个月97.6%。
- 保护性中和抗体滴度阳性比例从基线24%升至6个月88.4%,研究期间维持约90%。
- 抗Erns抗体流行率稳步下降,0和60个月分析的200份血清均未检出病毒RNA。
- 2018年以来未报告猪瘟疫情。
临床怎么用
- 在猪瘟防控中可参考全群基础免疫后仔猪2-3周龄接种、种猪每年两次的免疫程序。
- 结合抗E2抗体和中和抗体监测评估群体免疫水平,并监测Erns抗体和病毒RNA以判断病毒循环。
局限性
- 原文未报告对照设计、统计检验及混杂因素控制等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Subunit vaccines against classical swine fever (CSF) have been proposed as a safer alternative to modified live vaccines. Porvac®, based on the chimeric protein E2-CD154 (fusion of CSFV E2 glycoprotein and CD154), was registered in Cuba in 2017. This study reports seven years of Porvac® use in the Isle of Youth. In November 2017, all 30,000 domestic pigs were immunized twice within six weeks. Thereafter, piglets were vaccinated at 2-3 weeks of age and breeding stock twice annually. Serological monitoring showed a sharp rise in anti-E2 antibodies, from 43.5% before vaccination to 97.6% at six months post-vaccination (mpv). The fraction of animals with protective neutralizing antibody titres increased from 24% at baseline to 88.4% at six mpv and remained close to 90% throughout the study. A steady decline in anti-Erns antibody prevalence was observed, and viral RNA was undetectable in 200 sera analysed at 0 and 60 mpv. Importantly, no CSF outbreaks have been reported since 2018. The sustained population immunity; reduced Erns seropositivity, and absence of viral circulation strongly suggest that Porvac® has contributed to effective CSF control in this region.
引用
- Sordo-Puga Y, Sardina-González T, Pérez-Pérez D, et al. Herd immunity without evidence of viral circulation during seven years of vaccination with Porvac®, a subunit vaccine against classical swine fever. Vaccine. 2026. PMID: 42727400. doi:10.1016/j.vaccine.2026.129157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。